Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to determine if people with metastatic melanoma who receive
Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer
than people who may or may not have surgery but who receive conventional chemotherapy
including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects
in subjects who receive therapy with HSPPC-96.